Hauser & PharmaPrint In $20 Million Deal
Hauser has announced the signing of contracts valued at $20 million overthe next three years with California-based PharmaPrint. Under the terms of the agreement, Hauser will provide R&D services focused on Pharma-Print's herbal-based products, and will manufacture various botanical extracts in its Colorado facilities for delivery to the latter beginning early 1998.
Dean Stull, Hauser's chief executive, said that his company's expertise in natural products' purification, combined with PharmaPrint's technology and market access, "position both companies to become leaders in the dietary supplements industry." The news follows PharmaPrint's recent deal with American Home Products, valued at $43.5 million (Marketletter October 27).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze